Johannes Karges develops anti-cancer agents that work in a targeted manner, rather than adversely affecting the entire body.
Alnylam’s CEO on welcoming competition, turning a profit, and a ‘spine-tingling moment’
For the last 20 years Alnylam Pharmaceuticals has converted Nobel-winning research on RNA-based gene-silencing into medicines, winning approvals for drugs delivered to the liver. That’s